AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8208173 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum teaching only (control group).
Number of subjects: 3
Study 2479083 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of pancreatic enzyme substitution (Pancrease)
Number of subjects: 10
Study 2479083 — intervention group
Group type: COMPARATOR
Intervention: Regular dosage of pancreatic enzyme substitution (Pancrease)
Number of subjects: 10
Study 1096685 — intervention group
Group type: EXPERIMENTAL
Intervention: naphazoline hydrochloride 0.05%
Number of subjects: 51
Study 1096685 — intervention group
Group type: EXPERIMENTAL
Intervention: antazoline phosphate 0.5%
Number of subjects: 51
Study 1096685 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of naphazoline hydrochloride and antazoline phosphate
Number of subjects: 51
Study 1096685 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study 31536941 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemic clamp (plasma glucose: 3.1 ± 0.3 mmol/L)
Number of subjects: 25
Study 31536941 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemic clamp (plasma glucose: 5.8 ± 0.3 mmol/L)
Number of subjects: 25
Study 31536941 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of cognitive discrepancy between hypoglycaemia and normoglycaemia
Number of subjects: 25
Study 31536941 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with cognitive discrepancy
Number of subjects: 25
Study 27779565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (EX) for 12 weeks, 3 times per week, intensity increased from 40% to 70% of heart rate reserve
Number of subjects: 20
Study 27779565 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control (CON)
Number of subjects: 20
Study 26403986 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arsenic (Realgar‐Indigo naturalis formula, RIF) plus all‐trans retinoic acid (ATRA)
Number of subjects: 60
Study 26403986 — intervention group
Group type: COMPARATOR
Intervention: Intravenous arsenic trioxide (ATO) plus ATRA
Number of subjects: 60
Study 26403986 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arsenic (RIF) during maintenance treatment
Number of subjects: 60
Study 26403986 — intervention group
Group type: COMPARATOR
Intervention: Intravenous arsenic trioxide (ATO) during maintenance treatment
Number of subjects: 60
Study 23999661 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 g of n‐3 PUFA daily for six weeks
Number of subjects: 50
Study 23999661 — intervention group
Group type: COMPARATOR
Intervention: 2 g of olive oil daily for six weeks
Number of subjects: 50
Study 22165459 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain ropivacaine
Number of subjects: 60
Study 22165459 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with epinephrine 1:100,000
Number of subjects: 60
Study 18998188 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched yogurt (1.6 g esterified phytosterols, equivalent to 1.0 g free phytosterol)
Number of subjects: 15
Study 18998188 — intervention group
Group type: COMPARATOR
Intervention: Phytosterol-free placebo-controlled diet
Number of subjects: 15
Study 16452747 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dry dressing changes without pin-site care
Number of subjects: 118
Study 16452747 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pin-site care with a solution of one-half normal saline solution and one-half hydrogen peroxide
Number of subjects: 118
Study 16452747 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated discs (Biopatch) with weekly changes
Number of subjects: 118
Study 15233286 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral Analysis (SA) using 99mTc-HMPAO
Number of subjects: 17
Study 15233286 — intervention group
Group type: COMPARATOR
Intervention: Graphical Analysis (GA) using 99mTc-HMPAO
Number of subjects: 17
Study 11407040 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 26
Study 11407040 — intervention group
Group type: COMPARATOR
Intervention: Blade plate
Number of subjects: 26
Study 8990337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=336)
Number of subjects: 874
Study 8929232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin retard (6 mg)
Number of subjects: 343
Study 8929232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin retard
Number of subjects: 343
Study 2647578 — intervention group
Group type: EXPERIMENTAL
Intervention: arbaprostil 10 micrograms q.i.d.
Number of subjects: 124
Study 2647578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 750190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic PGF2a
Number of subjects: 0
Study 750190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic 15 Me PGF2a
Number of subjects: 0
Study 750190 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic 15 Me PGF2a
Number of subjects: 0
Study 30940489 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat Atkins diet (4 weeks)
Number of subjects: 0
Study 30940489 — intervention group
Group type: COMPARATOR
Intervention: Low fat Ornish diet (4 weeks)
Number of subjects: 0
Study 28347792 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 97
Study 28347792 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study 27872106 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glycine concentrations
Number of subjects: 2571
Study 27872106 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma serine concentrations
Number of subjects: 2571
Study 27872106 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFD1 rs2236225 polymorphism
Number of subjects: 2571
Study 27872106 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFD1 rs1076991 polymorphism
Number of subjects: 2571
Study 22893556 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized fetal growth norms (SGAcust)
Number of subjects: 1092
Study 22893556 — intervention group
Group type: COMPARATOR
Intervention: Population fetal growth norms (SGApop)
Number of subjects: 1092
Study 21057883 — intervention group
Group type: EXPERIMENTAL
Intervention: More teaching-intensive hospitals
Number of subjects: 8282802
Study 21057883 — intervention group
Group type: COMPARATOR
Intervention: Less teaching-intensive hospitals
Number of subjects: 8282802
Study 21057883 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medical group
Number of subjects: 8282802
Study 21057883 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgical group
Number of subjects: 8282802
Study 21057883 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcomes of readmission and death
Number of subjects: 8282802
Study 19448947 — intervention group
Group type: EXPERIMENTAL
Intervention: Stethoscopes used in pediatric units
Number of subjects: 0
Study 17304143 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.0-2.5 mg/kg per day)
Number of subjects: 21
Study 17304143 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine (4 g/day)
Number of subjects: 21
Study 17304143 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 21
Study 17304143 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 21
Study 14973100 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional incentive (30-min prepaid phone card provided concurrently with the survey)
Number of subjects: 1402
Study 14973100 — intervention group
Group type: COMPARATOR
Intervention: Conditional incentive (30-min prepaid phone card provided only upon receipt of completed survey)
Number of subjects: 1402
Study 11211372 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 11
Study 8878220 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin A therapy
Number of subjects: 239
Study 8878220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 8620046 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Chain Triglycerides (LCT)
Number of subjects: 0
Study 8620046 — intervention group
Group type: COMPARATOR
Intervention: Medium and Long Chain Triglycerides (MCT/LCT)
Number of subjects: 0
Study 6366346 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% aqueous solution of indomethacin
Number of subjects: 164
Study 6366346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 31842962 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 300
Study 31842962 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 27317036 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser visual guidance (LVG)
Number of subjects: 32
Study 27317036 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-dimensional vision
Number of subjects: 32
Study 26663250 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing without water (using disposable skin cleaning and caring materials)
Number of subjects: 500
Study 26663250 — intervention group
Group type: COMPARATOR
Intervention: Traditional bathing methods
Number of subjects: 500
Study 25074046 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab for 12 weeks
Number of subjects: 26
Study 25074046 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab for 24 weeks
Number of subjects: 26
Study 25074046 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 26
Study 22494677 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (2000 IU im) after first exposure
Number of subjects: 46
Study 22494677 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (2000 IU im) after second exposure
Number of subjects: 46
Study 22494677 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (2000 IU im) after third exposure
Number of subjects: 46
Study 19056078 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO compatible recipients
Number of subjects: 1002
Study 19056078 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO incompatible recipients
Number of subjects: 1002
Study 17599420 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic strategy targeting HbA(1c) level <6.0%
Number of subjects: 3537
Study 17599420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrate and statin therapy for lipid management
Number of subjects: 3537
Study 17599420 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure targeting <120 mm Hg
Number of subjects: 3537
Study 17599420 — intervention group
Group type: EXPERIMENTAL
Intervention: Various levels of loss of visual acuity at 4 years versus baseline
Number of subjects: 3537
Study 17599420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract extraction
Number of subjects: 3537
Study 17599420 — intervention group
Group type: EXPERIMENTAL
Intervention: Development or progression of diabetic macular edema
Number of subjects: 3537
Study 15691617 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg for 4 weeks
Number of subjects: 24
Study 15691617 — intervention group
Group type: COMPARATOR
Intervention: Bendroflumetazide 2.5 mg for 4 weeks
Number of subjects: 24
Study 11773924 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial patients (n=264)
Number of subjects: 599
Study 11773924 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=335)
Number of subjects: 599
Study 11773924 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 599
Study 11773924 — intervention group
Group type: COMPARATOR
Intervention: Trial patients vs Control subjects
Number of subjects: 599
Study 9794277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) - 12 weekly sessions of individual CT
Number of subjects: 0
Study 9794277 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 8560527 — intervention group
Group type: COMPARATOR
Intervention: Dextrose 2 mg/kg/min infused over 60 min with heparin and Intralipid (group C)
Number of subjects: 32
Study 8560527 — intervention group
Group type: COMPARATOR
Intervention: Dextrose 2 mg/kg/min infused over 60 min alone (group A)
Number of subjects: 32
Study 8560527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 4 mg/kg/min alone (group B)
Number of subjects: 32
Study 8560527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 4 mg/kg/min with heparin and Intralipid (group D)
Number of subjects: 32
Study 2155688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2.6 mg active drug per nostril, q.i.d.)
Number of subjects: 92
Study 2155688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 6104973 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (SL 75212)
Number of subjects: 6
Study 6104973 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 6104973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31371081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentanethaquine hydrochloride (PHC)
Number of subjects: 90
Study 27988180 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 27988180 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 25
Number of subjects: 0
Study 27988180 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25308868 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride 10 mg
Number of subjects: 12
Study 25308868 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride 25 mg
Number of subjects: 12
Study 23570280 — intervention group
Group type: EXPERIMENTAL
Intervention: Infumorph
Number of subjects: 154
Study 23570280 — intervention group
Group type: COMPARATOR
Intervention: Compounded morphine
Number of subjects: 154
Study 21255424 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography 'implementation intentions' (MI2) intervention
Number of subjects: 0
Study 21255424 — intervention group
Group type: COMPARATOR
Intervention: General breast cancer prevention informational intervention (C)
Number of subjects: 0
Study 19351732 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol and progesterone for 7 days
Number of subjects: 52
Study 19351732 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 52
Study 19351732 — intervention group
Group type: EXPERIMENTAL
Intervention: P-insensitive HA girls
Number of subjects: 52
Study 19351732 — intervention group
Group type: COMPARATOR
Intervention: Tanner 1-2 NC
Number of subjects: 52
Study 17722473 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis with nadroparin s.c. only during bed immobilization
Number of subjects: 300
Study 17722473 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis with nadroparin s.c. for 10 additional days after bed immobilization
Number of subjects: 300
Study 17722473 — intervention group
Group type: COMPARATOR
Intervention: Both groups (during thromboprophylaxis)
Number of subjects: 300
Study 14748902 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea (Echinilin)
Number of subjects: 282
Study 14748902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 11522495 — intervention group
Group type: EXPERIMENTAL
Intervention: HDV-insulin (0.1 U/kg)
Number of subjects: 9
Study 11522495 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (0.1 U/kg)
Number of subjects: 9
Study 11522495 — intervention group
Group type: EXPERIMENTAL
Intervention: HDV-insulin
Number of subjects: 9
Study 11522495 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 9
Study 9597414 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarctation of the aorta (1)
Number of subjects: 0
Study 9597414 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarctation of the aorta (2)
Number of subjects: 0
Study 9597414 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9597414 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarctation of the aorta (1) and (2)
Number of subjects: 0
Study 9597414 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of surgery (anastomosis or subclavian flap)
Number of subjects: 0
Study 7928912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (various concentrations) for 2 or 6.6 hours
Number of subjects: 374
Study 3302342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin suppository (4 x 125 mg)
Number of subjects: 105
Study 3302342 — intervention group
Group type: COMPARATOR
Intervention: Oral form of ampicillin (4 x 125 mg)
Number of subjects: 105
Study 31033625 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bilateral US-guided erector spinae plane (ESP) block
Number of subjects: 0
Study 31033625 — intervention group
Group type: COMPARATOR
Intervention: Standard (opioid-based) analgesia (Control group)
Number of subjects: 0
Study 29581161 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 302
Study 29581161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 27549570 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory nutrition promotion (CPNP) programme
Number of subjects: 1790
Study 27549570 — intervention group
Group type: COMPARATOR
Intervention: Government nutrition programmes only
Number of subjects: 1790
Study 26144575 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated FiO2 (A-FiO2)
Number of subjects: 80
Study 26144575 — intervention group
Group type: COMPARATOR
Intervention: Manual FiO2 (M-FiO2)
Number of subjects: 80
Study 22957521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control (insulin-dosing algorithm targeting blood glucose level of 80 to 110 mg/dL)
Number of subjects: 980
Study 22957521 — intervention group
Group type: COMPARATOR
Intervention: Standard care in the cardiac ICU
Number of subjects: 980
Study 22957521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control
Number of subjects: 980
Study 22957521 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 980
Study 21151978 — intervention group
Group type: EXPERIMENTAL
Intervention: AQP5 polymorphisms (specifically three of the five SNPs tested) in continuous smokers
Number of subjects: 429
Study 21151978 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype tests of AQP5 SNPs
Number of subjects: 429
Study 21151978 — intervention group
Group type: COMPARATOR
Intervention: Wild-type AQP5 in HBE16 cells under shear stress and cigarette smoke extract (CSE 10%)
Number of subjects: 429
Study 21151978 — intervention group
Group type: EXPERIMENTAL
Intervention: N228K AQP5 plasmid in HBE16 cells under shear stress and CSE
Number of subjects: 429
Study 17666497 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (25 mg or 50 mg every 14 days)
Number of subjects: 377
Study 17666497 — intervention group
Group type: COMPARATOR
Intervention: Oral olanzapine (5-20 mg/day)
Number of subjects: 377
Study 17666497 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone
Number of subjects: 377
Study 17666497 — intervention group
Group type: COMPARATOR
Intervention: Oral olanzapine
Number of subjects: 377
Study 17666497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 377
Study 15502112 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (bud/form) maintenance + relief (80/4.5 microg twice a day with 80/4.5 microg as-needed)
Number of subjects: 2760
Study 15502112 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol (bud/form) + SABA (terbutaline 0.4 mg)
Number of subjects: 2760
Study 15502112 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (bud) + SABA (terbutaline 0.4 mg)
Number of subjects: 2760
Study 15502112 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (bud/form) maintenance + relief
Number of subjects: 2760
Study 11925466 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined olive oil (rich in monounsaturated fatty acids, n = 18)
Number of subjects: 56
Study 11925466 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil (rich in MUFA and (n‐3)‐polyunsaturated fatty acids, n = 18)
Number of subjects: 56
Study 11925466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil (rich in (n‐6)‐PUFA, n = 20)
Number of subjects: 56
Study 9585655 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI), flexible dose, final dose 173.1 mg/day ± 56.3 mg/day
Number of subjects: 27
Study 9585655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8596757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 30
Study 2503346 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 174
Study 2503346 — intervention group
Group type: COMPARATOR
Intervention: Control group (no methadone)
Number of subjects: 174
Study 779502 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine 200 mg daily 6 days per week (regimen 1)
Number of subjects: 0
Study 779502 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine 100 mg three times weekly (regimen 2)
Number of subjects: 0
Study 779502 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine 300 mg weekly (regimen 3)
Number of subjects: 0
Study 779502 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine 600 mg every other week (regimen 4)
Number of subjects: 0
Study 779502 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine 600 mg on 2 consecutive days every 4 weeks (regimen 5)
Number of subjects: 0
Study 779502 — intervention group
Group type: COMPARATOR
Intervention: Clofazimine 200 mg daily 6 days per week (regimen 6)
Number of subjects: 0
Study 779502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone, starting with a small dosage and increasing to 100 mg daily 6 days per week (regimen 7)
Number of subjects: 0
Study 29744804 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled antipsychotic treatment for 12 weeks
Number of subjects: 33
Study 29744804 — intervention group
Group type: COMPARATOR
Intervention: Simple response conflict task
Number of subjects: 33
Study 29744804 — intervention group
Group type: COMPARATOR
Intervention: Simple fMRI task
Number of subjects: 33
Study 30376810 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed Intermittent Epidural Bolus (PIEB) 6 mL/h of ropivacaine 0.2%
Number of subjects: 84